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Introduction 
Myoclonus Dystonia (MD) (DYT11) is an early-onset hyperkinetic movement 
disorder with a prominent psychiatric phenotype caused by mutations in the ε-
sarcoglycan (SGCE) gene.(1) Although its precise function is unknown, 
multiple studies suggest ε-sarcoglycan to be involved in monoamine 
metabolism and neurotransmission. We report four patients with SGCE-
mutation-positive MD associated with low cerebrospinal fluid (CSF) levels of 
the serotonin metabolite, 5-hydroxyindoleacetic acid. 
 
Methods 
Cases were ascertained through (i) systematic searches of CSF 
Neurotransmitter Databases (National Hospital for Neurology and 
Neurosurgery, UK and University Children's Hospital, Heidelberg, Germany 
(Cases 1-3) and (ii) collaboration with clinicians (Case 4). SGCE mutation 
analysis was undertaken in diagnostic laboratories. Lumbar punctures were 
undertaken during investigation and CSF neurotransmitters analyzed using 
standardized protocols. CSF levels of the dopamine metabolite, homovanillic 
acid (HVA), serotonin metabolite, 5-HIAA (5-hydroxyindoleacetic acid) and 
pterin species were measured by high performance liquid chromatography. 
Blood serotonin levels were measured for Cases 1-3.   
 
Results 
Clinical and genetic characteristics are summarized in Figure 1A. In all cases, 
CSF 5-HIAA levels were below the lower limit of the normal reference range. 
All other CSF neurotransmitter metabolites were within normal expected 
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values, except Case 4 where HVA (88nmol/L, age related reference range, 
ARRR:145-324nmol/L) and tetrahydrobiopterin (6.8nM, ARRR:12-30nM) were 
also reduced (Figure 1A).  
 
Discussion 
We report four patients with SGCE-mutation positive MD associated with 
abnormal CSF 5-HIAA levels. To date, the CSF neurotransmitter profile of MD 
has not been delineated, as CSF neurotransmitter analysis is rarely 
undertaken in MD patients. Indeed when MD is clinically suspected, early 
genetic testing and molecular confirmation of the diagnosis typically negates 
the need for further clinical investigations.  
 
Isolated cerebral serotonin deficiency is increasingly recognized as a distinct 
clinical disorder (Figure 1B).(2, 3) A recent study showed ~20% of childhood-
onset movement disorders to be associated with reduced CSF 5-HIAA levels, 
49% of these demonstrating an isolated CSF 5-HIAA reduction.(4) Serotonin 
has an important role during neuronal development, influencing cell 
differentiation and synaptogenesis, and mood and motor control in the mature 
brain.(5) Alcohol ingestion has also been observed to transiently increase 
serotonergic neurotransmission in animal models, potentially explaining its 
beneficial effects in MD.(6) Notably, three patients in our study had normal 
blood serotonin levels, suggesting that serotonin dyshomeostasis in MD may 
be tissue-specific. 
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In contrast, the Sgce KO mouse model found no reduction in striatal serotonin 
and 5-HIAA levels compared to controls, although elevated HVA levels were 
inversely correlated with 5-HIAA levels.(7) This discrepancy may be due to 
inherent differences between striatal tissue and CSF, or possible region 
specific changes in the rodent brain. 
 
Reduced CSF HVA was observed in Case 4, with values towards the lower 
end of the normal range in Cases 1-3, a feature also seen in patients with 
primary neurotransmitter disorders (e.g. tyrosine hydroxylase deficiency) 
(Figure 1B), depression and alcoholism.(8, 9) As only one patient in our series 
had a definitively abnormal HVA level, its relevance in MD remains unclear.  
 
Our report suggests a possible link between MD and impaired brain serotonin 
homeostasis. Underlying mechanisms potentially include impaired cerebral 
serotonin production, metabolism or transport. Although not suggested as a 
routine investigation, it may be a useful future disease biomarker, which may 















            Low CSF 5-HIAA in Myoclonus Dystonia 
                                                                                                                              Peall et al 2017 
 6 
Authors’ Roles 
Kathryn J Peall: 1) Research project (a. conception, b. organization, c. 
execution), 2) Data (analysis or interpretation of the data), 3) Manuscript (A. 
writing of the first draft, b. review and critique) 
Joanne Ng: 1) Research project (a. conception, b. organization, c. 
execution), 2) Data (analysis or interpretation of the data), 3) Manuscript (A. 
writing of the first draft, b. review and critique) 
Marisela E Dy: 2) Data (analysis or interpretation of the data), 3) Manuscript 
(A. writing of the first draft, b. review and critique) 
Nutan Sharma: 2) Data (analysis or interpretation of the data), 3) Manuscript 
(A. writing of the first draft, b. review and critique) 
Simon Pope: 2) Data (analysis or interpretation of the data), 3) Manuscript 
(A. writing of the first draft, b. review and critique) 
Simon Heales: 2) Data (analysis or interpretation of the data), 3) Manuscript 
(A. writing of the first draft, b. review and critique) 
Jennifer R Friedman: 2) Data (analysis or interpretation of the data), 3) 
Manuscript (A. writing of the first draft, b. review and critique) 
Manju A Kurian: 1) Research project (a. conception, b. organization, c. 
execution), 2) Data (analysis or interpretation of the data), 3) Manuscript (A. 
writing of the first draft, b. review and critique) 
 
 
Financial Disclosures (for the preceding 12 months) 
KJP is funded by an MRC Clinician-Scientist Fellow, and is supported by an 
Academy of Medical Sciences Clinical Starter Grant and a Life Sciences 
Research Network Wales Post-Doctoral grant. MED and NS are funded by 
NINDS 5P01NS087997. JN is an MRC Research Training Fellow. MAK is a 
Wellcome Intermediate Fellow (WT098524/Z/12/Z). No other financial 












            Low CSF 5-HIAA in Myoclonus Dystonia 
                                                                                                                              Peall et al 2017 
 7 
References 
1. Peall KJ, Smith DJ, Kurian MA et al. SGCE mutations cause psychiatric 
disorders: clinical and genetic characterization. Brain. 2013;136(Pt 1):294-
303. 
2. Assmann B, Kohler M, Hoffmann GF, Heales S, Surtees R. Selective 
decrease in central nervous system serotonin turnover in children with 
dopa-nonresponsive dystonia. Pediatr Res. 2002;52(1):91-4. 
3. Meyer E, Carss KJ, Rankin J et al. Mutations in the histone 
methyltransferase gene KMT2B cause complex early-onset dystonia. Nat 
Genet. 2017;49(2):223-37. 
4. De Grandis E, Serrano M, Perez-Duenas B et al. Cerebrospinal fluid 
alterations of the serotonin product, 5-hydroxyindolacetic acid, in 
neurological disorders. J Inherit Metab Dis. 2010;33(6):803-9. 
5. Herlenius E, Lagercrantz H. Neurotransmitters and neuromodulators 
during early human development. Early Hum Dev. 2001;65(1):21-37. 
            Low CSF 5-HIAA in Myoclonus Dystonia 
                                                                                                                              Peall et al 2017 
 8 
6. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, 
abuse, and dependence: findings of animal studies. Biol Psychiatry. 
1994;36(6):395-421. 
7. Yokoi F, Dang MT, Li J, Li Y. Myoclonus, motor deficits, alterations in 
emotional responses and monoamine metabolism in epsilon-sarcoglycan 
deficient mice. J Biochem. 2006;140(1):141-6. 
8. Sher L, Oquendo MA, Li S et al. Lower CSF homovanillic acid levels 
in depressed patients with a history of alcoholism. 
Neuropsychopharmacology. 2003;28(9):1712-9. 
9. Willemsen MA, Verbeek MM, Kamsteeg EJ et al. Tyrosine 
hydroxylase deficiency: a treatable disorder of brain catecholamine 
biosynthesis. Brain. 2010;133(Pt 6):1810-22. 
 
Legend to Figure 1  
Figure 1A: Clinical, biochemical and genetic features of patients with 
SGCE-mutation positive Myoclonus Dystonia 
ARRR: Age Related Reference Range, LL: Lower Limbs, UL: Upper Limbs. 
Values in red: CSF values outside age adjusted reference range. 
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Figure 1B: Classification of primary and secondary monoamine 
neurotransmitter disorders  
AADC: Aromatic L-Amino Acid Decarboxylase, DAT: Dopamine Transporter, 
HIE: Hypoxic Ischaemic Encephalopathy, PKAN: Pantothenate kinase 
associated neurodegeneration, PTPS: 6-Pyruvoyl-Tetrahydropterin Synthase, 
VMAT2: Vesicular Monoamine Transporter 2. 
 
 
